MIN-117

MIN-117
Clinical data
Other names	WF-516
Identifiers
	IUPAC name (2S)-1-[4-(3,4-Dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol;
CAS Number	310392-94-0;
PubChem CID	9806065;
ChemSpider	7981825;
UNII	QM05G7NM4H;
Chemical and physical data
Formula	C25H25Cl2N3O
Molar mass	454.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OC[C@H](CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O;
	InChI InChI=1S/C25H25Cl2N3O4/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3/t18-/m0/s1; Key:XIYDIPLATGRHEC-SFHVURJKSA-N;

Short description: Chemical compound

MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD).^[2]^[3]^[4] It is described as a 5-HT_1A and 5-HT_2A receptor antagonist and inhibitor of serotonin and dopamine reuptake,^[4]^[5]^[6] and is also reported to possess affinity for the α_1A- and α_1B-adrenergic receptors.^[4]^[6] As of May 2015, MIN-117 is in phase II clinical trials for MDD.^[3] In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.^[7]

References

↑ "Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain". PLOS ONE 7 (8): e42589. 2012. doi:10.1371/journal.pone.0042589. PMID 22880045. Bibcode: 2012PLoSO...742589S.
↑ "Minerva Neuroscience". http://minervaneurosciences.com/.
↑ ^3.0 ^3.1 Minerva Neurosciences (2015). "Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates" (Press release). GlobalNewswire. Retrieved 2015-05-19.
↑ ^4.0 ^4.1 ^4.2 Minerva Neurosciences. "Investor Presentation March 2015". http://files.shareholder.com/downloads/AMDA-2MIFBM/0x0x813311/13B96B22-1D5F-470D-888B-8E1F47FE6AFA/Minerva_Investor_Presentation_-_March_2015.pdf.
↑ "Company Profile for Minerva Neurosciences Inc.". Reuters. http://in.reuters.com/finance/stocks/companyProfile?symbol=NERV.O.
↑ ^6.0 ^6.1 Dion, Don (2014). "Some Nerves Surrounding Minerva Neurosciences IPO". Seeking Alpha. http://seekingalpha.com/article/2285733-some-nerves-surrounding-minerva-neurosciences-ipo.
↑ "Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder" (in en-US). https://www.biospace.com/article/minerva-neurosciences-reports-topline-results-from-phase-2b-trial-of-min-117-in-major-depressive-disorder/.

External links

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/MIN-117. Read more

[KatoSaijo2012-1] "Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain". PLOS ONE 7 (8): e42589. 2012. doi:10.1371/journal.pone.0042589. PMID 22880045. Bibcode: 2012PLoSO...742589S.

[Minerva2015a-2] "Minerva Neuroscience". http://minervaneurosciences.com/.

[Minerva2015b-3] 3.0 ^3.1 Minerva Neurosciences (2015). "Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates" (Press release). GlobalNewswire. Retrieved 2015-05-19.

[Minerva2015c-4] 4.0 ^4.1 ^4.2 Minerva Neurosciences. "Investor Presentation March 2015". http://files.shareholder.com/downloads/AMDA-2MIFBM/0x0x813311/13B96B22-1D5F-470D-888B-8E1F47FE6AFA/Minerva_Investor_Presentation_-_March_2015.pdf.

[Reuters2015-5] "Company Profile for Minerva Neurosciences Inc.". Reuters. http://in.reuters.com/finance/stocks/companyProfile?symbol=NERV.O.

[SeekingAlpha2015-6] 6.0 ^6.1 Dion, Don (2014). "Some Nerves Surrounding Minerva Neurosciences IPO". Seeking Alpha. http://seekingalpha.com/article/2285733-some-nerves-surrounding-minerva-neurosciences-ipo.

[7] "Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder" (in en-US). https://www.biospace.com/article/minerva-neurosciences-reports-topline-results-from-phase-2b-trial-of-min-117-in-major-depressive-disorder/.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

v t e Adrenergic receptor modulators
α₁	Agonists: 6-FNE Amidephrine Anisodine Buspirone Cirazoline Corbadrine Desglymidodrine Dexisometheptene Dipivefrine Dopamine Droxidopa (L-DOPS) Ephedrine Epinephrine Etilefrine Etilevodopa Ethylnorepinephrine Indanidine Isometheptene L-DOPA (levodopa) L-Phenylalanine L-Tyrosine Melevodopa Metaraminol Methoxamine Methyldopa Midodrine Naphazoline Norepinephrine Octopamine (drug) Oxymetazoline Phenylephrine Phenylpropanolamine Pseudoephedrine Synephrine Tetryzoline Tiamenidine XP21279 Xylometazoline Antagonists: Abanoquil Adimolol Ajmalicine Alfuzosin Amosulalol Anisodamine Arotinolol Atiprosin Atypical antipsychotics (e.g., brexpiprazole, clozapine,Chemistry:Olanzapine
α₂	Agonists: (R)-3-Nitrobiphenyline 4-NEMD 6-FNE Amitraz Apraclonidine Brimonidine Cannabivarin Clonidine Corbadrine Detomidine Dexmedetomidine Dihydroergotamine Dipivefrine Dopamine Droxidopa (L-DOPS) Etilevodopa Ephedrine Ergotamine Epinephrine Etilefrine Ethylnorepinephrine Guanabenz Guanfacine Guanoxabenz L-DOPA (levodopa) L-Phenylalanine L-Tyrosine Lofexidine Medetomidine Melevodopa Methyldopa Mivazerol Naphazoline Norepinephrine Oxymetazoline Phenylpropanolamine Piperoxan Pseudoephedrine Rezatomidine Rilmenidine Romifidine Talipexole Tasipimidine Tetrahydrozoline Tiamenidine Tizanidine Tolonidine Urapidil Vatinoxan XP21279 Xylazine Xylometazoline Antagonists: 1-PP Adimolol Amesergide Aptazapine Atipamezole Atypical antipsychotics (e.g., asenapine, Chemistry:Brexpiprazole
β	Agonists: Abediterol Alifedrine Amibegron Arbutamine Arformoterol Arotinolol BAAM Bambuterol Befunolol Bitolterol Broxaterol Buphenine Carbuterol Carmoterol Cimaterol Clenbuterol Colterol Corbadrine Denopamine Dipivefrine Dobutamine Dopamine Dopexamine Droxidopa (L-DOPS) Ephedrine Epinephrine Etafedrine Etilefrine Etilevodopa Ethylnorepinephrine Fenoterol Formoterol Hexoprenaline Higenamine Indacaterol Isoetarine Isoprenaline Isoxsuprine L-DOPA (levodopa) L-Phenylalanine L-Tyrosine Levosalbutamol Mabuterol Melevodopa Methoxyphenamine Methyldopa Mirabegron Norepinephrine Orciprenaline Oxyfedrine PF-610355 Phenylpropanolamine Pirbuterol Prenalterol Ractopamine Procaterol Pseudoephedrine Reproterol Rimiterol Ritodrine Salbutamol Salmeterol Solabegron Terbutaline Tretoquinol Tulobuterol Vilanterol Xamoterol XP21279 Zilpaterol Zinterol Antagonists: Acebutolol Adaprolol Adimolol Afurolol Alprenolol Alprenoxime Amosulalol Ancarolol Arnolol Arotinolol Atenolol Befunolol Betaxolol Bevantolol Bisoprolol Bopindolol Bornaprolol Brefonalol Bucindolol Bucumolol Bufetolol Bufuralol Bunitrolol Bunolol Bupranolol Butaxamine Butidrine Butofilolol Capsinolol Carazolol Carpindolol Carteolol Carvedilol Celiprolol Cetamolol Cicloprolol Cinamolol Cloranolol Cyanopindolol Dalbraminol Dexpropranolol Diacetolol Dichloroisoprenaline Dihydroalprenolol Dilevalol Diprafenone Draquinolol Ecastolol Epanolol Ericolol Ersentilide Esatenolol Esprolol Eugenodilol Exaprolol Falintolol Flestolol Flusoxolol Hydroxycarteolol Hydroxytertatolol ICI-118,551 Idropranolol Indenolol Indopanolol Iodocyanopindolol Iprocrolol Isoxaprolol Isamoltane Labetalol Landiolol Levobetaxolol Levobunolol Levomoprolol Medroxalol Mepindolol Metipranolol Metoprolol Moprolol Nadolol Nadoxolol Nebivolol Nifenalol Nipradilol Oxprenolol Pacrinolol Pafenolol Pamatolol Pargolol Penbutolol Pindolol Practolol Primidolol Procinolol Pronethalol Propafenone Propranolol Ridazolol Ronactolol Soquinolol Sotalol Spirendolol SR 59230A Sulfinalol Talinolol Tazolol Tertatolol Tienoxolol Tilisolol Timolol Tiprenolol Tolamolol Toliprolol Xibenolol Xipranolol

MIN-117

Topic: Chemistry

See also

References

External links